Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Bladder cancer : ESMO Practice Guidelines for diagnosis, treatment and follow-up

Tools
- Tools
+ Tools

Bellmunt, Joaquim, Orsola, A., Leow, J. J., Wiegel, Thomas, De Santis, Maria and Horwich, Alan (2014) Bladder cancer : ESMO Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, Volume 25 (Supplement 3). iii40-iii48. doi:10.1093/annonc/mdu223 ISSN 0923-7534.

Research output not available from this repository.

Request-a-Copy directly from author or use local Library Get it For Me service.

Official URL: http://dx.doi.org/10.1093/annonc/mdu223

Request Changes to record.

Abstract

n Europe, an estimated 151 297 new cases of bladder cancer were diagnosed in 2012, with an age-standardised incidence rate (per 100 000 persons) of 17.7 for males and 3.5 for females. Overall, the annual crude incidence rate is 20.4/100 000. In 2012, there were 52 395 deaths from bladder cancer with an annual crude mortality rate of 7.1/100 000 [1]. Approximately 70% of patients with bladder cancer are >65 years of age.
The most common presenting symptom is painless haematuria, seen in >80% of patients. Others may also present with irritative symptoms such as dysuria, frequency or urgency. Symptoms of metastases such as bone or flank pain are rare. Most diagnosed cases of muscle-invasive bladder cancer (MIBC; 80%–90%) present as primary invasive bladder cancer. However, up to 15% of patients have a history of non-muscle-invasive bladder cancer (NMIBC), mainly high-risk cases.

Item Type: Journal Article
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Cancer Research Unit
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Journal or Publication Title: Annals of Oncology
Publisher: Oxford University Press
ISSN: 0923-7534
Official Date: 5 August 2014
Dates:
DateEvent
5 August 2014Published
Volume: Volume 25
Number: Supplement 3
Page Range: iii40-iii48
DOI: 10.1093/annonc/mdu223
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us